Nilsson E, von Euler H, Berendson J, Thörne A, Wersäll P, Näslund I, Lagerstedt A S, Narfström K, Olsson J M
Department of Chemical Engineering and Technology, Applied Electrochemistry, Royal Institute of Technology (KTH), Stockholm, Sweden.
Bioelectrochemistry. 2000 Feb;51(1):1-11. doi: 10.1016/s0302-4598(99)00073-2.
The electrochemical treatment (EChT) of tumours implies that tumour tissue is treated with a continuous direct current through two or more electrodes placed in or near the tumour. The treatment offers considerable promise of a safe, simple and relatively noninvasive anti-tumour therapy for treatment of localised malignant as well as benign tumours. Although more than 10,000 patients have been treated in China during the past 10 years, EChT has not yet been universally accepted. The reason for this is the lack of essential preclinical studies and controlled clinical trials. Uncertainties regarding the destruction mechanism of EChT also hinder the development of an optimised and reliable dose-planning methodology. This article reviews the collected Chinese and occidental experiences of the electrochemical treatment of tumours, alone and in combination with other therapies. The current knowledge of the destruction mechanism underlying EChT is presented along with different approaches towards a dose planning methodology. In addition, we discuss our view of different important parameters that have to be accounted for, if clinical trials are to be initiated outside of China.
肿瘤的电化学治疗（EChT）是指通过置于肿瘤内部或附近的两个或更多电极，用连续直流电对肿瘤组织进行治疗。该治疗方法为治疗局部恶性肿瘤和良性肿瘤提供了一种安全、简单且相对无创的抗肿瘤疗法，具有很大的前景。尽管在过去十年中中国已有一万多名患者接受了治疗，但EChT尚未被广泛接受。原因在于缺乏必要的临床前研究和对照临床试验。EChT破坏机制的不确定性也阻碍了优化且可靠的剂量规划方法的发展。本文综述了中国和西方在肿瘤电化学治疗方面的经验，包括单独治疗以及与其他疗法联合使用的情况。文中介绍了EChT潜在破坏机制的现有知识以及剂量规划方法的不同途径。此外，如果要在中国以外地区开展临床试验，我们还讨论了必须考虑的不同重要参数。
